Purified proteins, parvovirus antigens
February 2019—Binding Site’s Immunologicals Group has added to its line of products purified proteins to be used for the analysis and testing of hepatitis.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
NGS bacterial meningitis test
February 2019—Viracor Eurofins launched a 16S Next Generation Sequencing Bacterial Meningitis test for use in patients suspected of having bacterial meningitis.
Streck adds instrument to linearity control
February 2019—Streck Retic-Chex Linearity for BC is now assayed for the Beckman Coulter UniCel DxH 900 analyzer. Retic-Chex Linearity for BC is designed to establish the reportable range and linearity of analyzers that report the reticulocyte parameter.
Dragonfly, Celgene expand collaboration
February 2019—Dragonfly Therapeutics has entered into a new agreement with Celgene to discover, develop, and commercialize immunotherapies for patients with solid and hematological cancers.
Pembrolizumab approved for Merkel cell carcinoma
February 2019—The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
LGC acquires SeraCare Life Sciences
February 2019—London-based LGC announced the acquisition of SeraCare Life Sciences. SeraCare provides quality control materials for infectious disease testing through its Accurun reagents and next-generation sequencing reference materials through its Seraseq products for oncology, noninvasive prenatal testing, and inherited disease testing.
ArcherDx cDx assay gets breakthrough designation
February 2019—ArcherDx announced that the FDA granted a breakthrough device designation for its companion diagnostic assay application.
NxGen MDx offers hereditary cancer panel
February 2019—NxGen MDx introduced its NxGen MDx Hereditary Cancer Panel, which tests for variants in 32 genes known to cause certain forms of hereditary cancer.
Quidel high-sensitivity troponin I test gains CE mark
February 2019—Quidel has received the CE mark for its TriageTrue High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be used as an aid in the diagnosis of myocardial infarction for use with the company’s Triage MeterPro instrument.
FDA expands approval of olaparib
February 2019—Olaparib (Lynparza, AstraZeneca) has been approved by the FDA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line, platinum-based chemotherapy.